[HTML][HTML] Recent advances on P-glycoprotein (ABCB1) transporter modelling with in silico methods
L Mora Lagares, M Novič - International Journal of Molecular Sciences, 2022 - mdpi.com
ABC transporters play a critical role in both drug bioavailability and toxicity, and with the
discovery of the P-glycoprotein (P-gp), this became even more evident, as it plays an …
discovery of the P-glycoprotein (P-gp), this became even more evident, as it plays an …
5-Oxo-hexahydroquinoline: An attractive scaffold with diverse biological activities
Oxo-hexahydroquinoline (5-oxo-HHQ) represents a biologically attractive fused heterocyclic
core. Various synthetic analogs of 5-oxo-HHQ have been synthesized and assessed for …
core. Various synthetic analogs of 5-oxo-HHQ have been synthesized and assessed for …
Effect of the force field on molecular dynamics simulations of the multidrug efflux protein P-glycoprotein
Molecular dynamics (MD) simulations have been used extensively to study P-glycoprotein
(P-gp), a flexible multidrug transporter that is a key player in the development of multidrug …
(P-gp), a flexible multidrug transporter that is a key player in the development of multidrug …
5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells
Multidrug resistance (MDR) in cancer cells is often associated with overexpression of ATP-
binding cassette (ABC) transporters, including P-glycoprotein (P-gp/ABCB1), multidrug …
binding cassette (ABC) transporters, including P-glycoprotein (P-gp/ABCB1), multidrug …
Multi-stage screening to predict the specific anticancer activity of Ni (II) mixed-ligand complex on gastric cancer cells; biological activity, FTIR spectrum, DNA binding …
LH Saremi, KD Noshahr, A Ebrahimi… - … Acta Part A: Molecular …, 2021 - Elsevier
The anticancer activity of a transition metal complex with [Ni (L 1) 2 L 2] H 2 O (where L 1
and L 2 were acetylacetonato (acac) and 2-aminopyridine (2-ampy), respectively) was …
and L 2 were acetylacetonato (acac) and 2-aminopyridine (2-ampy), respectively) was …
HFIP-mediated strategy towards β-oxo amides and subsequent Friedel-Craft type cyclization to 2‑quinolinones using recyclable catalyst
A simple and cost-effective 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol (HFIP)-mediated protocol
for the synthesis of β-oxo amides has been described by using amines and β-keto esters as …
for the synthesis of β-oxo amides has been described by using amines and β-keto esters as …
5-Oxohexahydroquinolines bearing 4-pyridyl methyl carboxylate as P-glycoprotein inhibitors and multidrug resistance reversal agents in cancer cells
S Ranjbar, FF Lashkarian, M Khoshneviszadeh… - Journal of Molecular …, 2023 - Elsevier
Multidrug resistance (MDR) limits the therapeutic effect of conventional chemotherapeutic
agents as well as novel targeted anticancer drugs. An important mechanism of MDR is the …
agents as well as novel targeted anticancer drugs. An important mechanism of MDR is the …
A binuclear iron (III) complex of 5, 5′-dimethyl-2, 2′-bipyridine as cytotoxic agent
T Kondori, N Akbarzadeh-T, H Ghaznavi, Z Karimi… - Biometals, 2020 - Springer
The binuclear iron (III) complex (1), namely,{[Fe (5, 5′-dmbpy) 2 (OH 2)] 2 (µ-O)}(NO 3) 4
with a distorted octahedral coordination, formed by four nitrogen and two oxygen atoms, was …
with a distorted octahedral coordination, formed by four nitrogen and two oxygen atoms, was …
Diverse targeted approaches to battle multidrug resistance in cancer
N Shankaraiah, S Nekkanti, O Ommi… - Current Medicinal …, 2019 - ingentaconnect.com
The efficacy of successful cancer therapies is frequently hindered by the development of
drug resistance in the tumor. The term 'drug resistance'is used to illustrate the decreased …
drug resistance in the tumor. The term 'drug resistance'is used to illustrate the decreased …
Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters
Background ABC transporter-mediated multidrug resistance (MDR) remains a major
obstacle for cancer pharmacological treatment. Some tyrosine kinase inhibitors (TKIs) have …
obstacle for cancer pharmacological treatment. Some tyrosine kinase inhibitors (TKIs) have …